Quoin Pharmaceuticals Ltd (QNRX): Rasio rega marang prakiraan pendapatan

Logo perusahaan publik Quoin Pharmaceuticals Ltd. (QNRX)

Quoin Pharmaceuticals (QNRX) is focusing its development on clinical trials for treatments targeting rare genetic skin pathologies. The forward price-to-sales valuation illustrates this trend, with the latest reading at . The foundation for growth is exceptional pricing power derived from the patent for the drug QRX-003. Meanwhile, risk is posed by biotech behemoths seeking to acquire promising orphan drug developments to dominate the dermatology sector.

Quoin Pharmaceuticals Ltd - Rasio kapitalisasi marang dodolan sing dikarepake QNRX (periode 04.07.2022 - 17.11.2026)

Rincian metrik komprehensif lan analitis Quoin Pharmaceuticals Ltd (QNRX)

Produk sing diprodhuksi Quoin Pharmaceuticals Ltd.

Forward P/S relates current market capitalization to expected revenue, reflecting the valuation's sensitivity to future cash flow forecasts. For Quoin Pharmaceuticals (QNRX), which is developing a pipeline of drugs for rare dermatoses, this indicator assesses the commercialization potential of QRX-003, allowing the company's forward P/S chart to determine whether the market price is fair relative to sales prospects.